Pfizer’s chief strategist Andrew Baum, M.D., is leaving his post two years after pivoting from a career-long tenure as a ...

There might be room for two titans in the obesity business, but a third player might have a uniquely marketable option.

Pfizer (PFE) executive Andrew Baum, hired in 2024 as its Chief Strategy and Innovation Officer to overhaul the company’s strategic direction, is leaving the drugmaker later this year, according to a ...

The healthcare giant has been investing heavily in its future growth.

Pfizer and Astellas have received the US Food and Drug Administration (FDA) acceptance for priority review of their ...

Pfizer's Chief Strategy and Innovation Officer, Andrew Baum, is transitioning to a new role and will eventually leave the company.

U.S. Food and Drug Administration "enforcement in the social media space has historically been somewhat limited, but recent ...

The FDA has scolded Pfizer over Facebook ads for the cancer drug Adcetris, accusing the Big Pharma of failing to adequately ...

Pfizer executive Andrew Baum, a former Citi analyst, has left his role as an executive vice president and chief strategy and ...

Pfizer, by contrast, appears diversified but diffuse—its pipeline may contain value, but that value is not yet organized into ...

Before deciding to walk away from the building, Pfizer tried to list nearly half of the 164,000-square-foot campus for ...

Global drug maker Pfizer (PFE) and biotech firm Amgen (AMGN), each valued at over HK$1T ($153B), are among 22 strategic ...